Development of immunoadjuvants for immunotherapy of cancer
- 1 June 2001
- journal article
- review article
- Published by Elsevier BV in International Immunopharmacology
- Vol. 1 (7), 1249-1259
- https://doi.org/10.1016/s1567-5769(01)00055-8
Abstract
No abstract availableThis publication has 59 references indexed in Scilit:
- Maturation of Human Dendritic Cells by Cell Wall Skeleton ofMycobacterium bovisBacillus Calmette-Guérin: Involvement of Toll-Like ReceptorsInfection and Immunity, 2000
- Human MD-1 Homologue Is a BCG-Regulated Gene Product in Monocytes: Its Identification by Differential DisplayBiochemical and Biophysical Research Communications, 1999
- CpG motifs in bacterial DNA trigger direct B-cell activationNature, 1995
- Interferon- .GAMMA. as a Marker for the Effective Cancer Immunotherapy with BCG-Cell Wall Skeleton.Proceedings of the Japan Academy, Series B, 1994
- A SYNTHETIC SINGLE-STRANDED DNA, POLY(dG, dC), INDUCES TNTERFERON-α/β AND -γ, AUGMENTS NATURAL KILLER ACTIVITY, AND SUPPRESSES TUMOR GROWTHJapanese Journal of Cancer Research, 1988
- Syntheses of Trehalose Monomycolate and Related Compounds, and Their Lethal Toxicity and Adjuvant ActivityJournal of Carbohydrate Chemistry, 1986
- Lethal and adjuvant activities of cord factor (trehalose-6,6'-dimycolate) and synthetic analogs in mice.CHEMICAL & PHARMACEUTICAL BULLETIN, 1985
- Minimal structural requirements for adjuvant activity of bacterial peptidoglycan derivativesBiochemical and Biophysical Research Communications, 1974
- The chemical structure of the cord factor of Mycobacterium tuberculosisBiochimica et Biophysica Acta, 1956
- STUDIES ON THE VIRULENCE OF TUBERCLE BACILLIThe Journal of Experimental Medicine, 1950